Tetra Pharm Technologies and Kvantify, two Danish companies, have partnered to accelerate the discovery of novel drug candidates targeting the endocannabinoid system (ECS). The collaboration will leverage quantum computing, AI, and computer-aided drug design to revolutionize drug discovery. Martin Rose, CEO of Tetra Pharm Technologies, and Hans Henrik Knudsen, CEO of Kvantify, believe the partnership will expedite drug development and lead to significant advancements in therapeutic options. The collaboration will involve comprehensive screening of nearly 1,000 molecular combinations suspected of acting as ligands to endocannabinoid receptors.
Tetra Pharm Technologies and Kvantify Collaborate to Expedite Drug Discovery
Tetra Pharm Technologies and Kvantify, two Danish companies, have announced a strategic partnership aimed at accelerating the discovery and development of novel drug candidates that target the endocannabinoid system (ECS). The collaboration will leverage quantum computing, artificial intelligence (AI), and computer-aided drug design to potentially revolutionize the drug discovery process.
Martin Rose, Chief Executive Officer of Tetra Pharm Technologies, expressed optimism about the partnership, stating that it would expedite their drug development process and significantly expand their pipeline of promising drug candidates in 2024. The collaboration is expected to transform the landscape of ECS-targeted drug discovery, potentially leading to significant advancements in therapeutic options for patients.
Exploring the Complexities of Endocannabinoid Receptors
The partnership will delve into the complexities of endocannabinoid receptors and their interactions with potential drug candidates from Tetra Pharm Technologies’ pipeline. This approach is expected to not only advance the existing pipeline significantly but also lead to new discoveries within the field.
Tetra Pharm Technologies currently has 11 drug candidates in its pipeline, each targeting specific receptors with distinct modes of action. The company pursues a distinct mode of action at the receptor level for each pipeline candidate based on their scientists’ understanding of the endocannabinoid system. This includes identifying which receptors they aim to target and which receptors to avoid to minimize side effects.
Leveraging Kvantify’s Platform for Comprehensive Screening
The collaboration will involve a comprehensive screening of nearly 1,000 molecular combinations suspected of acting as ligands to endocannabinoid receptors. This screening will be conducted using Kvantify’s CNS module, providing Tetra Pharm Technologies additional insight into the propensity for blood-brain-barrier penetration.
Dr. Morten Allesø, Chief Scientific Officer at Tetra Pharm Technologies, highlighted the benefits of the Kvantify platform, stating that it enables them to screen much broader and to more effectively identify key structural attributes of their drug candidates. This will guide their in-vitro cellular pharmacology and ultimately their CMC activities.
The Potential Impact of the Collaboration
Nils Anton Berglund, Head of Strategic Alliances at Kvantify, emphasized the potential impact of the collaboration. He stated that the endocannabinoid system has been under-leveraged in drug discovery and represents a significant opportunity for innovation. With Tetra Pharm Technologies’ deep knowledge of endocannabinoid biology and the atomistic level precision that Kvantify’s CNS drug discovery platform can deliver, the collaboration could uncover groundbreaking new science for the benefit of patients worldwide.
Hans Henrik Knudsen, Chief Executive Officer at Kvantify, echoed these sentiments, stating that the combination of Tetra Pharm Technologies’ novel drug delivery technology with Kvantify’s computational drug discovery platform creates an exciting synergy that will facilitate more rapid and efficient development of novel drugs.
About Tetra Pharm Technologies and Kvantify
Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018. The company is focused on the research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system.
Kvantify, established in 2022, is a Danish company that delivers software solutions and services to tackle challenging and valuable problems in areas such as biotechnology and medicine. The company comprises more than 65 experts in a broad range of fields, from quantum computing and software engineering to mathematics, physics, cheminformatics, and computational chemistry.
External Link: Click Here For More
